MedTrace Logo

Dupilumab Effects Against Aeroallergen Challenge

NCT05720325 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-03-06

No results posted yet for this study

Summary

The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.

Conditions

  • Asthma, Allergic

Interventions

DRUG

Dupilumab

Dupixent is an interleukin-4 receptor alpha antagonist

OTHER

House Dust Mites (HDM)

House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

OTHER

Placebo

Inert placebo administered to placebo arms of study.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Regeneron Pharmaceuticals

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Sunil K Ahuja, MD · University of Texas Health Science Center San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-29
Primary Completion
2026-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05720325 on ClinicalTrials.gov